1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

@inproceedings{Wong20151yearRO,
  title={1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy},
  author={Ian Y. H. Wong and Xuan Shi and R Gangwani and Paul Songbo Zhao and Lawrence P. L. Iu and Qing Li and Alex Lap-Ki Ng and Xiaoxin Li},
  booktitle={BMC ophthalmology},
  year={2015}
}
BACKGROUND To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal ischemia and visual loss can be resulted from the standard-dose PDT. Half-dose PDT has proved to produce similar results and safety profile in treating central serous chorioretinopathy. Half-dose PDT… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 29 references

a review

  • Y Imamura, M Engelbert, T Iida, vasculopathy et al. Polypoidal choroidal
  • Surv Ophthalmol. 2010;55(6):501–15. Submit your…
  • 2015
2 Excerpts

Similar Papers

Loading similar papers…